Holen Sie sich die Stockscreener-App
27.41
0.88%
0.24
Handel nachbörslich:
27.42
0.01
+0.04%
Schlusskurs vom Vortag:
$27.17
Offen:
$27.29
24-Stunden-Volumen:
14.53M
Relative Volume:
0.39
Marktkapitalisierung:
$6.33B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
52.50
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
-10.31%
1M Leistung:
+38.16%
6M Leistung:
-39.71%
1J Leistung:
-24.20%
1-Tages-Spanne:
$26.93
$27.77
1-Wochen-Bereich:
$25.62
$30.72
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
27.41 | 6.28B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
16.62 | 52.70B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
114.16 | 48.35B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.38 | 41.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.95 | 40.84B | 17.52B | 1.58B | 1.06B | 1.3428 |
UTHR
United Therapeutics Corp
|
570.40 | 24.25B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Data Breach Lawsuits Test Hims And Hers Health Valuation And Momentum - Yahoo Finance
Hims, Hims & Hers class actions allege data breach exposed sensitive patient information - Class Action Lawsuits
Hims & Hers, Novo Nordisk: FDA GLP-1 Compounding Ruling May Actually Favor Hims (NYSE:NVO) - Seeking Alpha
+3.19% for Hims & Hers Health stock as gap higher shifts short-term outlook - Traders Union
HIMS Stock On The Mend? New Testosterone Push Builds As GLP-1 Gold Rush Gets Crowded - Stocktwits
Hims & Hers Health, Inc. (HIMS) is a top-ranked momentum stock: Should you buy? - MSN
HIMS vs. TDOC: Which Digital Health Stock Offers Better Upside Now? - The Globe and Mail
Hims & Hers Health stock price forecast: $25.00 support in focus as HIMS falls 5.66% - Traders Union
EXCLUSIVE: Enhanced CEO Says Its Performance Medicine Platform Is The Real Prize Beyond The Games - Benzinga
Hims & Hers Health shares dip amid rising selling pressure - Traders Union
Hims & Hers Expands Digital-First Access to Personalized Healthcare - Yahoo Finance
Hims & Hers Health, Inc. (HIMS) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Hims & Hers Health, Inc. (Derivatives) Analytics: Price Dynamics, Quarterly Returns, and Annual Price Changes in USD - CryptoRank
Hims & Hers Health, Inc. (Derivatives) Exchanges HIMS Markets | Buy & Sell & Trade - CryptoRank
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today - Yahoo Finance
-5.04% for Hims & Hers stock as weight-loss drug guidelines take center stage - Traders Union
HIMS stock loses weight: CEO's massive 272x pay gap with workers tips the scales ahead of shareholder vote - MSN
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz - The National Law Review
HIMS Stock Loses Weight: CEO's Massive 272x Pay Gap With Workers Tips The Scales Ahead Of Shareholder Vote - Stocktwits
Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Direct - GuruFocus
Dan Kenger Hims & Hers The Orange Pill Bottle Is Out And A Whole New Kind Of Healthcare Brand Is In - BuzzFeed
Hims Board Shakeup Highlights Marketing Focus And Customer Growth Metrics - Yahoo Finance
Hims & Hers' Legal Chief Earned $4.8M In 2025 - Law360
OMCL vs. HIMS: Which Stock Should Value Investors Buy Now? - Yahoo Finance Singapore
Hims & Hers nominates Kofi Amoo-Gottfried to its board of directors - marketscreener.com
Hims & Hers Health, Inc. (Derivatives) Price | HIMS Price Today, Live Chart, USD converter, Market Capitalization - CryptoRank
Let’s Talk About Sex: The Identity of Intimacy - Hims & Hers Newsroom
Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means - MarketBeat
Hims & Hers Nominates DoorDash and Meta Veteran Kofi Amoo-Gottfried to Board of Directors - citybiz
Hims & Hers nominates ex-DoorDash CMO to board - Investing.com
[ARS] Hims & Hers Health, Inc. SEC Filing - Stock Titan
Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors - Hims & Hers Newsroom
SEC Form DEFA14A filed by Hims & Hers Health Inc. - Quantisnow
Hims & Hers (NYSE: HIMS) 2026 proxy details growth, control and pay - Stock Titan
-3.83% for Hims & Hers stock as broader selling pressure hits markets - Traders Union
Investor relations - HIMS Investor Relations
A Look at Hims & Hers Health Inc (HIMS) After 3.8% Decline -- GF Value $36.82 vs Price $29.39 - GuruFocus
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Hims & Hers Health, Inc. (HIMS) suffers a larger drop than the general market: Key insights - MSN
Bank of America resets Hims and Hers stock price target - thestreet.com
Should You Buy HIMS Stock Following Friday's Rally? - Yahoo Finance
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Hims & Hers builds scalable data-driven personalized care platform - MSN
Hims & Hers back in red as FDA doubles down on GLP-1 compounders - MSN
2026-04-26 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Hims & Hers Health, Inc. (HIMS) and Encourages Stockholders to Learn More About the Investigation | NYSE:HIMS | Press Release - Stockhouse
Hims & Hers expands personalized digital healthcare platform - MSN
Novo Nordisk sues Hims & Hers over compounded Wegovy, calls for permanent sales ban: HIMS stock tanks - MSN
Hims and Hers Expands Its Technology-Driven Consumer Health Platform - MSN
A Look At Hims & Hers Health (HIMS) Valuation After Fresh GLP-1 Analyst Endorsement And Pharma Partnerships - Yahoo Finance
Why Is Hims & Hers Health Stock Down 12% Today? - MSN
HIMS Stock Slides Premarket: Rival Telehealth Firm Ro Launches Aggressive Price Cuts In GLP-1 Subscription Fight - Stocktwits
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Hims Hers Health Inc-Aktie (HIMS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Okupe Oluyemi | Chief Financial Officer |
Apr 20 '26 |
Option Exercise |
8.65 |
12,553 |
108,531 |
282,599 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 20 '26 |
Sale |
29.96 |
19,645 |
588,615 |
262,954 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 17 '26 |
Option Exercise |
5.01 |
6,184 |
30,982 |
288,051 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 16 '26 |
Sale |
25.90 |
36,922 |
956,147 |
281,867 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 17 '26 |
Sale |
27.83 |
18,005 |
501,158 |
270,046 |
0.63%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):